Want to see HK:1228 full AI Analyst Report?
CANbridge Pharmaceuticals Inc. (1228) Ratios
CANbridge Pharmaceuticals Inc. Ratios
HK:1228's free cash flow for Q2 2026 was $-82.64M. For the 2026 fiscal year, HK:1228's free cash flow was decreased by $-42.00K and operating cash flow was $-82.59M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.24 | 0.09 | 0.64 | 1.82 | 4.37 |
| Quick Ratio | 0.20 | 0.08 | 0.61 | 1.78 | 4.30 |
| Cash Ratio | 0.15 | 0.02 | 0.38 | 1.62 | 4.01 |
| Solvency Ratio | 0.05 | -0.73 | -0.81 | -1.17 | -5.33 |
| Operating Cash Flow Ratio | -0.08 | -0.25 | -0.85 | -1.01 | -3.16 |
| Short-Term Operating Cash Flow Coverage | -5.44 | -7.99 | -11.74 | -10.46 | -19.02 |
| Net Current Asset Value | $ -397.15M | $ -545.95M | $ -225.29M | $ 111.67M | $ 612.58M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.10 | 1.16 | 0.36 | 0.22 | 0.06 |
| Debt-to-Equity Ratio | -0.05 | -0.29 | -3.57 | 0.50 | 0.08 |
| Debt-to-Capital Ratio | -0.05 | -0.40 | 1.39 | 0.33 | 0.07 |
| Long-Term Debt-to-Capital Ratio | -0.02 | -0.03 | -0.20 | 0.03 | 0.00 |
| Financial Leverage Ratio | -0.48 | -0.25 | -9.94 | 2.28 | 1.29 |
| Debt Service Coverage Ratio | -8.76 | -13.75 | -10.46 | -13.48 | -31.17 |
| Interest Coverage Ratio | -42.67 | -39.67 | -40.96 | -66.73 | -212.78 |
| Debt to Market Cap | 0.01 | 0.57 | 0.08 | 0.04 | 0.04 |
| Interest Debt Per Share | 0.04 | 0.34 | 0.36 | 0.38 | 0.59 |
| Net Debt to EBITDA | 0.63 | -0.38 | -0.05 | 0.65 | 0.66 |
| Profitability Margins | |||||
| Gross Profit Margin | 73.13% | 63.81% | 62.37% | 61.91% | 60.25% |
| EBIT Margin | -185.46% | -400.12% | -359.57% | -603.52% | -3446.38% |
| EBITDA Margin | -161.15% | -386.23% | -331.90% | -575.69% | -3395.98% |
| Operating Profit Margin | -185.46% | -400.12% | -356.32% | -579.91% | -2102.46% |
| Pretax Profit Margin | 29.65% | -520.10% | -368.26% | -612.21% | -3456.26% |
| Net Profit Margin | 29.65% | -520.10% | -368.26% | -612.21% | -3456.26% |
| Continuous Operations Profit Margin | 29.65% | -520.10% | -368.26% | -612.21% | -3456.26% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | -15.99% | 129.99% | 103.35% | 105.57% | 164.39% |
| Return on Assets (ROA) | 8.96% | -378.91% | -95.82% | -68.87% | -120.67% |
| Return on Equity (ROE) | -4.33% | 93.28% | 952.14% | -156.69% | -155.32% |
| Return on Capital Employed (ROCE) | 31.96% | 93.09% | -543.70% | -108.03% | -92.70% |
| Return on Invested Capital (ROIC) | 32.86% | 100.53% | -358.86% | -98.74% | -87.88% |
| Return on Tangible Assets | 13.38% | -903.47% | -118.81% | -76.27% | -128.02% |
| Earnings Yield | 1.41% | -834.08% | -99.51% | -52.68% | -153.36% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.30 | 5.09 | 3.29 | 4.14 | 3.41 |
| Payables Turnover | 0.04 | 0.08 | 0.20 | 0.28 | 0.28 |
| Inventory Turnover | 0.65 | 3.90 | 4.41 | 3.06 | 0.92 |
| Fixed Asset Turnover | 97.77 | 23.39 | 0.94 | 0.63 | 1.05 |
| Asset Turnover | 0.30 | 0.73 | 0.26 | 0.11 | 0.03 |
| Working Capital Turnover Ratio | -0.13 | -0.31 | 1.89 | 0.19 | 0.07 |
| Cash Conversion Cycle | -9360.14 | -4224.79 | -1673.99 | -1097.73 | -781.75 |
| Days of Sales Outstanding | 110.45 | 71.72 | 110.80 | 88.07 | 107.07 |
| Days of Inventory Outstanding | 559.35 | 93.66 | 82.82 | 119.22 | 396.33 |
| Days of Payables Outstanding | 10029.94 | 4390.17 | 1867.61 | 1305.01 | 1285.15 |
| Operating Cycle | 669.80 | 165.38 | 193.62 | 207.28 | 503.40 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.08 | -0.29 | -0.66 | -0.66 | -6.23 |
| Free Cash Flow Per Share | -0.08 | -0.29 | -0.75 | -0.74 | -6.29 |
| Dividend Paid and CapEx Coverage Ratio | -6368.67 | -1165.67 | -6.81 | -8.08 | -110.10 |
| Capital Expenditure Coverage Ratio | -6368.67 | -1165.67 | -6.81 | -8.08 | -110.10 |
| Operating Cash Flow Coverage Ratio | -2.38 | -0.90 | -1.96 | -1.81 | -11.27 |
| Operating Cash Flow to Sales Ratio | -0.76 | -1.44 | -2.70 | -3.56 | -18.84 |
| Free Cash Flow Yield | -3.64% | -230.84% | -83.82% | -34.41% | -84.36% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 76.65 | -0.12 | -1.00 | -1.90 | -0.65 |
| Price-to-Sales (P/S) Ratio | 21.02 | 0.62 | 3.70 | 11.62 | 22.54 |
| Price-to-Book (P/B) Ratio | -3.07 | -0.11 | -9.57 | 2.97 | 1.01 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -27.49 | -0.43 | -1.19 | -2.91 | -1.19 |
| Price-to-Operating Cash Flow Ratio | -27.49 | -0.43 | -1.37 | -3.27 | -1.20 |
| Price-to-Earnings Growth (PEG) Ratio | -0.74 | -0.01 | 0.05 | 0.02 | 0.17 |
| Enterprise Value Multiple | -12.42 | -0.54 | -1.16 | -1.37 | -0.01 |
| Enterprise Value | 1.00B | 178.34M | 397.71M | 621.84M | 8.55M |
| EV to EBITDA | -12.42 | -0.54 | -1.16 | -1.37 | -0.01 |
| EV to Sales | 20.01 | 2.10 | 3.87 | 7.87 | 0.27 |
| EV to Free Cash Flow | -26.17 | -1.46 | -1.25 | -1.97 | -0.01 |
| EV to Operating Cash Flow | -26.17 | -1.46 | -1.43 | -2.21 | -0.01 |
| Tangible Book Value Per Share | -0.87 | -1.28 | -0.27 | 0.57 | 6.81 |
| Shareholders’ Equity Per Share | -0.75 | -1.12 | -0.09 | 0.73 | 7.36 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.11 | 0.20 | 0.24 | 0.19 | 0.33 |
| Net Income Per Share | 0.03 | -1.04 | -0.89 | -1.14 | -11.43 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | -0.16 | 1.30 | 1.02 | 1.01 | 1.00 |
| Research & Development to Revenue | 0.90 | 2.96 | 2.50 | 3.94 | 13.72 |
| SG&A to Revenue | 1.68 | 1.68 | 0.87 | 1.38 | 4.67 |
| Stock-Based Compensation to Revenue | 0.10 | 0.09 | 0.19 | 0.34 | 0.98 |
| Income Quality | -2.58 | 0.28 | 0.73 | 0.58 | 0.55 |
Currency in CNY
